Once you have Acrobat Reader open on your computer, click on the Comment tab at the right of the toolbar:

This will open up a panel down the right side of the document. The majority of tools you will use for annotating your proof will be in the Annotations section, pictured opposite. We’ve picked out some of these tools below:

1. **Replace (Ins) Tool** – for replacing text.
   
   Strikes a line through text and opens up a text box where replacement text can be entered.

   **How to use it**
   - Highlight a word or sentence.
   - Click on the Replace (Ins) icon in the Annotations section.
   - Type the replacement text into the blue box that appears.

2. **Strikethrough (Del) Tool** – for deleting text.
   
   Strikes a red line through text that is to be deleted.

   **How to use it**
   - Highlight a word or sentence.
   - Click on the Strikethrough (Del) icon in the Annotations section.

3. **Add note to text Tool** – for highlighting a section to be changed to bold or italic.
   
   Highlights text in yellow and opens up a text box where comments can be entered.

   **How to use it**
   - Highlight the relevant section of text.
   - Click on the Add note to text icon in the Annotations section.
   - Type instruction on what should be changed regarding the text into the yellow box that appears.

4. **Add sticky note Tool** – for making notes at specific points in the text.
   
   Marks a point in the proof where a comment needs to be highlighted.

   **How to use it**
   - Click on the Add sticky note icon in the Annotations section.
   - Click at the point in the proof where the comment should be inserted.
   - Type the comment into the yellow box that appears.
5. **Attach File Tool** – for inserting large amounts of text or replacement figures.

   ![Attach File Icon]

   Inserts an icon linking to the attached file in the appropriate place in the text.

   **How to use it**
   - Click on the Attach File icon in the Annotations section.
   - Click on the proof to where you’d like the attached file to be linked.
   - Select the file to be attached from your computer or network.
   - Select the colour and type of icon that will appear in the proof. Click OK.

---

6. **Drawing Markups Tools** – for drawing shapes, lines and freeform annotations on proofs and commenting on these marks.

   ![Drawing Markups Icons]

   Allows shapes, lines and freeform annotations to be drawn on proofs and for comment to be made on these marks.

   **How to use it**
   - Click on one of the shapes in the Drawing Markups section.
   - Click on the proof at the relevant point and draw the selected shape with the cursor.
   - To add a comment to the drawn shape, move the cursor over the shape until an arrowhead appears.
   - Double click on the shape and type any text in the red box that appears.

---

END
Clinical course and management of acute and chronic viral hepatitis during pregnancy


Received June 2014; accepted for publication August 2014

SUMMARY. Pregnancy is a para-physiologic condition, which usually evolves without any complications in the majority of women, even if in some circumstances moderate or severe clinical problems can also occur. Among complications occurring during the second and the third trimester very important are those considered as concurrent to pregnancy such as hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, HELLP syndrome and acute fatty liver of pregnancy. The liver diseases concurrent to pregnancy typically occur at specific times during the gestation and they may lead to significant maternal and foetal morbidity and mortality. Commonly, delivery of the foetus, even preterm, usually terminates the progression of these disorders. All chronic liver diseases, such as chronic viral hepatitis, autoimmune hepatitis, Wilson’s disease, and cirrhosis of different aetiologies may cause liver damage, independently from pregnancy. In this review we will also comment the clinical implications of pregnancies occurring in women who received a orthotopic liver transplantation (OLT). Therefore, the management of immunosuppressive therapy before and after the delivery in women who received liver transplant is becoming a relevant clinical issue. Finally, we will focus on acute and chronic viral hepatitis occurring during pregnancy, on management of advanced liver disease and we will review the literature on the challenging issue regarding pregnancy and OLT.

Keywords: anti-viral therapy, liver disease, liver transplant, pregnancy.

INTRODUCTION

Pregnancy is a paraphysiologic condition, which usually evolves without any complications in the majority of women, even if in some circumstances moderate or severe clinical problems can also occur. Concerning the complications occurring during the second and the third trimester of pregnancy, a peculiar attention should be paid to those involving the liver, commonly referred as concurrent to pregnancy. Among these, we can found liver diseases unique to pregnancy, such as hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, HELLP syndrome and acute fatty liver of pregnancy [1,2]. However, the majority of liver disease pre-exist to pregnancy (Table 1) [1].

The liver diseases concurrent to pregnancy typically occur at specific times during the gestation and they may lead to significant maternal and foetal morbidity and mortality. Usually, most of the drugs are forbidden in pregnancy, due to their teratogenicity, but the risks and benefits of their use must be considered case by case. Commonly, delivery of the foetus, even preterm, usually terminates the progression of these disorders [2].

All chronic liver diseases, such as chronic viral hepatitis, autoimmune hepatitis, Wilson’s disease and cirrhosis of different aetiologies may cause liver damage, independently from pregnancy [3]. On the other hand, the first group is comprehensive of liver diseases that can occur during pregnancy, but not expressly related to it (such as acute viral hepatitis sustained by both major and minor hepatotropic virus) [3]. Furthermore, in this review, we will also comment the clinical implications of pregnancies occurring in women who received a orthotopic liver transplantation (OLT) [4]. In fact, it has recently been reported a significant increase of women that become pregnant after OLT. In United States, more than 3000 females of childbearing age have undergone OLT. Therefore, the management of immunosuppressive therapy before and after the delivery...
in women who received liver transplant is becoming a relevant clinical issue [4].

In our review, we will focus on acute and chronic viral hepatitis occurring during pregnancy, on management of advanced liver disease and we will review the literature on the challenging issue regarding pregnancy and OLT.

**ACUTE VIRAL HEPATITIS**

Acute viral hepatitis can be acquired during pregnancy (concurrent disease). If we refer only to hepatotropic viruses, the incidence during of pregnancy is almost the same as compared to the general population. Less common during pregnancy is the occurrence of viral hepatitis due to nonhepatotropic viruses.

Acute viral hepatitis is responsible of most cases of jaundice in pregnant women [1]. In the majority of cases, the clinical course is benign but sometimes cholestasis is manifest and can be prolonged up to puerperium. The major concern is the risk of infection to the foetus (vertical transmission). There is no clear evidence of teratogenic effect of hepatitis viruses in the first trimester [2]. Acute hepatitis acquired during pregnancy does not involve the risk of foetal congenital anomalies, except for Cytomegalovirus (CMV) infection, and the only complication is related to an increase of preterm delivery [2].

**Nonhepatotropic viruses**

**Cytomegalovirus**

Cytomegalovirus infection, which usually evolves asymptotically, has a high risk of vertical transmission and is responsible for major foetal abnormalities (Table 2) [5]. Commonly, pregnancy is not affected by the clinical course of infection, which is indolent in immunocompetent subjects [5]. Laboratory serological tests are the main clues to diagnose the CMV infection. Prevention is difficult because the virus is ubiquitous and the contact is frequent. Although controversial, some practices might minimize the risk for congenital infection [5]. The saliva and urine of infected children are significant sources of CMV infection. Preventive measures such as frequent hand washing, avoiding to share drinking glasses or eating with utensils of young children, and further stay away from them (avoiding kissing mouth or cheek) appear to be generally acceptable [5,6].

Now, no therapeutic options during pregnancy are available. Recent data obtained from literature have focused the efficacy of preventive administration of CMV immunoglobulins or antiviral drugs (Valacyclovir) to pregnant women with primary CMV infection to reduce the rate of vertical transmission and improve neonatal outcome [7]. The risk of mother-to-foetus transmission is higher when infection is acquired in the first trimester. On the contrary, risk of foetal damages is higher for infections acquired during the last trimester. For this reason, CMV seronegative women must be screened along the pregnancy with serological tests. CMV infection of the mother does not involve any risk. No therapeutic options aimed to protect the foetus are available for women infected during pregnancy, but new strategies are still ongoing. Until now, the only option to evaluate together with the mother in case of foetal infection is the termination of pregnancy, considering the high probability of foetal abnormalities [7].

**Herpes simplex virus**

Herpes simplex virus (HSV) infection is rare, but potentially lethal because it may cause fulminant hepatitis, with acute liver failure, especially if it occurs in the third trimester. The rate of mortality in untreated individuals is more than 80% [8]. Moreover, the hepatitis is anicteric in 90% of cases, so that the clinical suspicion arises in mostly asymptomatic patients with elevated transaminases (more than 3 times u.I.n.) and normal or mildly elevated bilirubin, often without the typical mucocutaneous lesions [8,9]. Serological tests to confirm diagnosis include HSV-IgM and HSV-PCR. It has been shown that viral load and transaminases levels are related to disease severity [9]. During pregnancy, the seroconversion rate is about 2% of women susceptible to HSV [9,10]. The serotypes that may cause of hepatitis are HSV-1 and HSV-2 in both primary and latent infections [9].

The premature delivery is not indicated in these cases, as the therapy with acyclovir or vidarabine is effective. The treatment must be started immediately because is life saving for the mother and the foetus [9–11]. Acyclovir is a nucleoside analogue antiviral agent, which is active, and it is recommended for use only when the potential benefit outweighs the potential risks to the foetus [12]. Moreover, in the case of suspected herpes simplex dissemination and

---

**Table 1 Liver diseases concurrent or related to pregnancy, according to trimester of gestation and liver involvement**

<table>
<thead>
<tr>
<th>Pre-existing or concurrent liver disease</th>
<th>Viral Hepatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Acute (HAV, HBV, HCV, HEV, CMV, HSV)</td>
</tr>
<tr>
<td></td>
<td>2. Chronic (HBV, HCV)</td>
</tr>
<tr>
<td></td>
<td>Autoimmune hepatitis</td>
</tr>
<tr>
<td></td>
<td>Wilson’s disease</td>
</tr>
<tr>
<td></td>
<td>Cirrhosis (different aetiologies)</td>
</tr>
<tr>
<td>Pregnancy-related diseases</td>
<td>1st Trimester:</td>
</tr>
<tr>
<td></td>
<td>Hyperemesis gravidarum</td>
</tr>
<tr>
<td></td>
<td>2nd Trimester:</td>
</tr>
<tr>
<td></td>
<td>Intrahepatic cholestasis of pregnancy</td>
</tr>
<tr>
<td></td>
<td>3rd Trimester:</td>
</tr>
<tr>
<td></td>
<td>Intrahepatic cholestasis of pregnancy</td>
</tr>
<tr>
<td></td>
<td>Eclampsia</td>
</tr>
<tr>
<td></td>
<td>HELLP syndrome</td>
</tr>
<tr>
<td></td>
<td>Acute fatty liver of pregnancy</td>
</tr>
</tbody>
</table>
Table 2 Clinical features of acute hepatitis due to hepatotropic and nonhepatotropic viruses in pregnancy

<table>
<thead>
<tr>
<th>Latency</th>
<th>CMV</th>
<th>HSV</th>
<th>HAV</th>
<th>HBV</th>
<th>HCV</th>
<th>HEV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Asymptomatic or flu-like Yes, if</td>
<td>Potentially lethal</td>
<td>Mild, rarely lethal</td>
<td>Usually asymptomatic</td>
<td>Usually asymptomatic</td>
<td>Lethal</td>
<td></td>
</tr>
<tr>
<td>Foetal Abnormalities</td>
<td>Contracted as primary infection Yes</td>
<td>Yes, but rare</td>
<td>Yes rare, preterm delivery</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Vertical transmission</td>
<td>Yes</td>
<td>Probable</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

Hepatotropic viruses

Hepatitis A virus

Hepatitis A virus (HAV) can cause clinical complications if it occurs during the second/third trimester of pregnancy. Most of the cases are anicteric and usually mild; fulminant hepatitis is rare [1]. It has been generally accepted that pregnancy itself does not show a negative impact on the course of hepatitis A infection. However, acute HAV hepatitis during pregnancy may be associated with a higher risk of maternal complications and therefore early delivery is indicated only in cases with severe liver dysfunction at the third trimester of gestation [13]. In Western countries, HAV is not frequent. However, in developing countries, there is a high incidence of fulminant hepatitis, probably favoured by a concomitant condition of malnutrition. In serious cases, hospitalization is required especially when nausea and vomiting are severe in the last quarter and induction of premature labour may be occur. However, commonly HAV hepatitis does not represent an indication for Caesarean section, or early termination of pregnancy [14]. Although intrauterine transmission is rare, it has been described in the presence of high levels of viral load at delivery [15]. When HAV infection is diagnosed in the third trimester, the foetus must be protected against the virus by administration of immune globulin within 48 h before the birth. Breastfeeding is not contraindicated [16].

Hepatitis E virus

Hepatitis E virus (HEV) hepatitis is rare in Western countries, but it is endemic in several areas of Africa, Asia and Central America, where, if acquired during pregnancy, may show a fulminant course with a mortality rate in one of six pregnancies [17]. Although in Western countries this is not a frequent occurrence, the HEV incidence is increased in Europe as well, especially for genotype 3 [1]. A recent French study has reported that 90% of acute hepatitis E acquired in the indigenous route, so that it looks like that current HEV epidemiology is going to change [17].

The severe clinical course of HEV infection in pregnancy differs among different Countries. It is conceivable that malnutrition and poor social conditions are the main co-factors promoting this evolution [18,19]. The reason to explain the greater susceptibility to HEV infection in pregnant women is still not known. The hypothesis of the reduced immunological activity and hormonal factors could be considered [20]. Acute HEV infection carries high mortality rates (15–25%) in pregnant women, especially in the third trimester, in association with acute liver failure, eclampsia and haemorrhages [21]. This is very common in developing countries, due to the emergence of genotype 3 [22]; the level of viremia seems to be likely associated with the severity of the disease during pregnancy [23]. The effect of acute HEV infection on clinical course of pregnancy in Western countries is still not known [22]. Vertical transmission occurs in 50% of cases and the infection is always symptomatic with high rates of morbidity (hepatitis, prematurity, hypothermia and hypoglycaemia) and mortality in the newborns [21].

No data are available on antiviral drugs for HEV. Treatment is only supportive. There are some reports concerning ribavirin-based treatment, but the teratogenic effect excludes any potential use in pregnant women. In case of life-threatening condition of the mother, termination of pregnancy is the rule [20–22]. Researches to develop an anti-HEV vaccine are underway [2,21].

Hepatitis B virus

All pregnant women are routinely tested for HBsAg at first visit during gestation to screen hepatitis B virus (HBV) infection. Acute HBV hepatitis is characterized by the absence of clinical complications during the course of pregnancy, but it carries high risk of mother-to-foetus viral transmission. This is particularly frequent if the mother is HBeAg positive and has been infected during the third trimester of gestation (50–80%), but the risk of transmission is lower when mother is anti-HBe positive (25%), or if she is asymptomatic carrier (5%) [1]. The risk of transmission is very low in case of maternal infection during the first or second trimester of pregnancy, but increases up to 50–70% if hepatitis occurs in the third trimester of pregnancy or soon after birth. The main risk factor for transmission is the high viral load [24]. Consequently, antiviral therapy during the third trimester has the goal to reduce...
viremia and so lowering the risk of perinatal transmission [24–26].

Both telbivudine and tenofovir can be taken to prevent intrauterine and perinatal HBV transmission during the last trimester of pregnancy in HBsAg-positive mother with high levels of viremia (serum HBV-DNA ≥ 10⁶ copies/mL) but without significant ALT increase. The drug can be discontinued soon after the delivery if breastfeeding is planned or within 3 months.

Infected newborns may become chronic HBsAg carriers in 80–90% of cases together with subclinical hepatic dysfunction, although they rarely will develop neonatal hepatitis. Perinatal transmission can be prevented with the use of anti-HBV vaccine and in association with hepatitis B immunoglobulin (HBIG) at birth with a percentage of success of about 95%. Patients at high risk of infection can be immunized before or during pregnancy by HBV vaccination without any risk for the foetus [2,24]. As regard HBV/HDV co-infection in pregnancy, there are very few data in literature.

Hepatitis C virus
The frequency of acute hepatitis C virus (HCV) infection during pregnancy is approximately calculated 0.4–6.0% [1]. These percentages increase in groups at high risk of infection (like anti-HIV positive, intravenous drug users). HCV infection can be acquired during pregnancy, but it does not affect the course of the pregnancy. The risk of vertical transmission is very low (3–10%) and it is determined by the same risk factors of chronic hepatitis but no therapy is available so far to avoid the contagion [27]. Routine screening is not recommended for HCV infection, but it should be useful at least in ‘at risk’ groups to start immediately after delivery the therapy [1]. Risk of vertical transmission is higher during delivery, due to contamination with blood fluid, but it can also occur by transplacental crossing. After the delivery, maternal breastfeeding is not absolutely contraindicated because risk of viral transmission is very low during lactation and it is recommended to pay attention to nipple abrasions [1,27] (http://www.cdc.gov/breastfeeding/disease/hepatitis.htm).

CHRONIC VIRAL HEPATITIS

Chronic viral hepatitis does not adversely affect the course of pregnancy, but it carries the risk of vertical transmission of the virus. Overall, chronic viral hepatitis is the most frequent pre-existing liver disease and they need to be followed through the whole period of pregnancy and overall after delivery.

HBV infection
HBV is an important global health problem, because of high risk of perinatal viral transmission. Before the adoption of HBIG, approximately 70–90% of infants born to HBeAg-positive mothers may became chronically infected by HBV [26]. HBV infection does not significantly modify the clinical course of pregnancy either fertility or conception unless the woman has liver cirrhosis or liver failure [28–30]. Moreover, chronic HBV infection does not increase maternal or foetal morbidity and mortality, although a recent study has shown an increased risk of diabetes mellitus, ante-partum haemorrhages and life-threatening preterm labour [30]. On the other hand, in the presence of cirrhosis, the risk to develop significant perinatal complications and poor pregnancy outcome is higher [31]. Moreover, cirrhotic pregnant women have usually higher spontaneous rates of maternal complications such as placental abruption, gestational hypertension and peripartum haemorrhages [1]. By the contrary, pregnancy does not influence the course of chronic HBV infection and usually it is not considered as a possible worsening factor [24].

Nowadays, the risk of perinatal transmission, which represents in many areas of the world the primary source of persistence of HBV chronic infection, has focused the attention to the management of HBV infection during pregnancy. The risk is very high in HBeAg-positive patients with high viral load, but conflicting data exist about the potential role of different HBV genotypes in influencing transmission [24,32].

Among maternal risk factors affecting vertical or perinatal transmission, we also mention placental diseases or complications appearing during labour and breastfeeding, which is another major source of infection [24].

Together with the immunoprophylaxis, the choice of correct antiviral therapy plays a major role in chronic HBV-infected women. Not all available drugs for treatment of chronic HBV infection can be used during pregnancy, and they have an important role to avoid an exacerbation of disease that can occur in case of drug discontinuation, especially soon after the delivery, with high risk of occurrence of fulminant hepatitis causing a life-threatening condition both for mother and foetus [1,25].

Drugs used for the treatment of chronic hepatitis B (CHB) include recombinant interferon (IFN), pegylated interferon (PEG-IFN) and Nucleos(t)ides analogues (NAs). NAs are classified as nucleosides (lamivudine, telbivudine, emtricitabine and entecavir) or nucleotides (adefovir and tenofovir). All these drugs have been approved in Europe for CHB treatment, while PEG-IFN and emtricitabine are not licensed for HBV treatment in most European countries. Because of their possible teratogenicity, only drugs classified in category C or B can be used during gestation. According to FDA classification, lamivudine, entecavir and adefovir are classified as ‘C’, while telbivudine and tenofovir are classified as drugs of category B (Table 3). Until now, the more appropriate drug is tenofovir because many data are available about the safety profile in pregnancy.
Furthermore, several data above safety of tenofovir are reported in HIV patients showing very low rate of congenital abnormalities [33]. By contrast, PEG-IFN is absolutely contraindicated because of high teratogenicity risk. In fact, women or partners of patients treated with PEG-IFN or in childbearing age should use a good contraception system until three to 6 months after stopping antiviral therapy [34].

Regarding to the different pharmacological features and teratogenicity risks of drugs for treating a young woman chronically HBV infected that wish to become pregnant should dispose her pregnancy and should be educated about safety profile of drugs during pregnancy. According to the last EASL guidelines, the therapeutic approach may be different based on the severity of liver damage: in women that want to become pregnant and do not have an advanced fibrosis, it is advisable to delay therapy after the delivery; in women with an advanced fibrosis or cirrhosis, therapy is mandatory [25]. During pregnancy, therapy must be based on a NA of category B, possibly tenofovir. If pregnancy is accidental and not planned, therapy should be adjusted and modified with a NA of category B [1].

HBV infection can be transmitted from mother-to-foetus at delivery. This risk, as mentioned before, correlates with viral load and HBeAg positivity. The prevention of HBV perinatal transmission is traditionally based on the combination of passive and active immunization with HBIG and HBV vaccination. Such a strategy, however, may not be effective in a proportion of newborns from highly viremic women (serum HBV-DNA >10^6–7 copies/mL), which carry a risk of vertical HBV transmission more than 10% despite administration of HBIG and vaccination. In these cases, the use of NAs before delivery may reduce viral loads and

### Table 3 Drugs for liver diseases and their use in women during pregnancy and after delivery

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>FDA pregnancy</th>
<th>Effect on conception</th>
<th>Effect on foetus</th>
<th>Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiviral drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acyclovir</td>
<td>B</td>
<td>Unknown</td>
<td>No</td>
<td>No data</td>
<td>Unsafe</td>
</tr>
<tr>
<td>Boceprevir</td>
<td>C</td>
<td>Unknown</td>
<td>No</td>
<td>No data</td>
<td>Unsafe</td>
</tr>
<tr>
<td>Entecavir</td>
<td>C</td>
<td>Unknown</td>
<td>No</td>
<td>No data</td>
<td>Unsafe</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>C</td>
<td>Unknown</td>
<td>No</td>
<td>No increases in birth defects overall</td>
<td></td>
</tr>
<tr>
<td>Peg-IFN</td>
<td>C</td>
<td>Teratogenic</td>
<td>Malformation</td>
<td>Unsafe</td>
<td></td>
</tr>
<tr>
<td>Ribavirin</td>
<td>X</td>
<td>Teratogenic</td>
<td>Teratogenic</td>
<td>Unsafe</td>
<td></td>
</tr>
<tr>
<td>Telaprevir</td>
<td>B</td>
<td>No data</td>
<td>No</td>
<td>Unsafe</td>
<td></td>
</tr>
<tr>
<td>Telbivudine</td>
<td>B</td>
<td>Unknown</td>
<td>No adverse effects in animals at doses as high as 37 times human dose</td>
<td>Possibly unsafe, excreted into the milk of lactating rat</td>
<td></td>
</tr>
<tr>
<td>Tenofovir</td>
<td>B</td>
<td>Unknown</td>
<td>No data</td>
<td>Unsafe</td>
<td></td>
</tr>
<tr>
<td>Valacyclovir</td>
<td>B</td>
<td>Unknown</td>
<td>No teratogenicity but limited data</td>
<td>Unsafe</td>
<td></td>
</tr>
<tr>
<td><strong>Diuretics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spironolactone</td>
<td>C</td>
<td>No</td>
<td>Unknown</td>
<td>Unsafe</td>
<td></td>
</tr>
<tr>
<td>Furosemide</td>
<td>C</td>
<td>No</td>
<td>No</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>β-blockers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propranolol</td>
<td>C</td>
<td>Unknown</td>
<td>IUGR, bradycardia, hypoglycaemia, Distress neonatal distress during labour</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Nadolol</td>
<td>C</td>
<td>No</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Possible unsafe (mainly at high dose)</td>
</tr>
<tr>
<td><strong>Vasoactive drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasopressin</td>
<td>C</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>Immunosuppressive drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>D</td>
<td>Unknown</td>
<td>22% malformations, 45% first trimester abortion</td>
<td>Unsafe</td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>C</td>
<td>Unknown</td>
<td>Prematurity risk</td>
<td>Unsafe</td>
<td>Possible unsafe, very low rate excreted in milk</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>C</td>
<td>Probable</td>
<td>Respiratory, renal dysfunction, birth defects</td>
<td>Safe</td>
<td></td>
</tr>
<tr>
<td>Prednisone</td>
<td>B</td>
<td>No</td>
<td>Very low rate of malformation (4%)</td>
<td>Safe</td>
<td></td>
</tr>
<tr>
<td>Mycofenolate</td>
<td>D</td>
<td>Yes</td>
<td>Birth defects</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

© 2014 John Wiley & Sons Ltd
therefore improve the effectiveness of HBIG and vaccination [35].

Therapy with lamivudine and, more recently, with telbivudine [36] during the last trimester in HBsAg-positive women with high viral load has been shown to be safe and to reduce the risk of intrauterine and perinatal transmission of HBV if given in addition to passive and active vaccination by HBIG and HBV vaccination after delivery. No controlled clinical trial of tenofovir to prevent perinatal transmission has been carried out until now.

There is not contraindication of breastfeeding for HBsAg-positive mother, even if HBV-DNA has been found in maternal milk [37]. No studies are available about safety of NAs use during the breastfeeding. For mothers on antiviral therapy with lamivudine or tenofovir, breastfeeding is not recommended because few data are available about the safety of antiviral exposure during breastfeeding [33,37]; however, due to low oral bioavailability of tenofovir in maternal milk, the newborn should not considered to be at risk [33,38,39].

As regarding to HBV/HDV co-infection, clinical course of HDV infection in pregnancy is similar in pregnant and nonpregnant women, although the clinical suspicion of this possible disease should arise in pregnant women with acute or chronic hepatitis B with a reactivation or hypertransaminasemia, testing for anti-HDV. This is extremely uncommon; however, because the vaccination for hepatitis B, when given to newborn infants, is almost uniformly effective against hepatitis D. Vertical transmission has not been shown, so early delivery is not necessary. Breastfeeding is safe, and vertical transmission can be avoided using HBV immunoprophylaxis [38].

**HCV infection**

Prevalence of HCV infection in pregnant women ranges between 1% and 2% in the United States and Europe, but it could increase up to 8% in some developing countries. HCV mother-to-child transmission (MTCT) has been clearly documented, with reported rates of about 5–10% [1,40].

Pathogenesis of HCV infection in pregnancy and during the neonatal period remains poorly understood. During gestation, a modulation of immune responses differs between the different stages of pregnancy [41,42]. In fact, at the same time, the maternal immune system must develop tolerance to paternal alloantigens to prevent maternal immune aggression against the foetus and maintain active immunity against HCV to protect both mother and foetus from the infection [41].

Although HCV affects a significant number of women of reproductive age, few studies have examined the impact of chronic HCV infection on pregnancy outcomes. Pregnancy does not seem to adversely affect the clinical course of HCV infection [43]. The majority of pregnant anti-HCV-positive women are asymptomatic. It is possible to observe during pregnancy a decrease of aminotransferases and an increase of HCV viral load, followed by an inversion of parameters during the postpartum period [1,43]. It has also been observed an increase of cases with cholestasis of pregnancy in anti-HCV-positive women [44]. The benign course of disease observed during pregnancy is attributed to the production of endogenous IFN by foetus and placenta [45]. The ALT levels decrease in association with viral load increase observed during the third trimester of pregnancy in women chronically infected by HCV could conceivably be explained by a pregnancy-associated decline in immune-mediated hepatocellular destruction and change of immunological state [40,46].

Multiple host factors have been shown to increase the risk of HCV MTCT; some of them are unchangeable, such as elevated viral load, co-infection with HIV, abuse of drugs and alcohol, other are mainly related to delivery management including amniocentesis and prolonged rupture of membranes [42]. Viral transmission can occur both in the uterus and during delivery. Indeed, perinatal HCV transmission is almost restricted to women with detectable HCV-RNA in the peripheral blood and MTCT rarely occurs if the maternal viral load remains below 100 000 HCV-RNA IU/mL [47]. However, there is a broad overlap in the levels of plasma HCV-RNA between transmitting and non-transmitting mothers [48].

The risk of vertical transmission is related to viral load. Hence, the achievement of viral clearance would be desirable before pregnancy because there are no drugs for HCV infection usable during gestation to reduce the risk of transmission.

Women with HCV infection can plan a pregnancy, and they must be educated about high teratogenicity risks of therapy during pregnancy. HCV-infected women, treated with standard therapeutic approach, must attend at least 6 months before becoming pregnant. If they accidentally become pregnant, therapy must be stopped and the mother should be informed for the risks of teratogenicity [1,49,50].

HCV-infected pregnant women do not need special monitoring, but only prenatal routine care as noninfected pregnant women. Delivery modalities usually do not influence vertical transmission, and Caesarean section is not considered a modality to prevent vertical transmission [43].

Data on transmission of HCV during lactation are contradictory. It has been suggested a correlation between disease activity (raised transaminases and HCV-RNA positive) and detection of HCV-RNA in breast milk resulting a chance of increased disease transmission by this route [42,49]. On the other hand, in several studies, transmission of HCV by breastfeeding has not been demonstrated, so there are no specific contraindications of breastfeeding in HCV-infected women [1,50]. Infected children can be treated with the available options but usually they can be
treated only after the third year of age because of the adverse effects of treatment on growth [51]. However, spontaneous resolution of infection has been observed both in mother during the postpartum period and in foetus [45].

No data have been published about safety of boceprevir and telaprevir in pregnant women. Their use is actually contraindicated in patients taking oral contraceptive containing ethinylestradiol and norethindrone so that alternative methods of nonhormonal contraception should be used [52].

ADVANCED CHRONIC LIVER DISEASES

Advanced chronic liver diseases, irrespectively of their aetiology, involve sexual dysfunctions with amenorrhoea and infertility because of hormonal alterations [3,53]. In fact, most women with decompensated cirrhosis are infertile and have menstrual abnormalities, caused by hypothalamic-pituitary dysfunction due to reduced level of gonadotropin-releasing hormone and reduced sex circulating steroid hormones [2]. Moreover, when portosystemic shunts are present, oestradiol and testosterone levels are increased [1].

Once pregnancy has initiated, high risks for mother and baby, such as prematurity, pulmonary hypertension, rupture of varices and bleeding may occur. A study carried out in a large cohort of pregnant women with cirrhosis reported a rate of decompensation of 15% [54].

However, if liver function is in the normal range and there is no clinically relevant portal hypertension, pregnancy can be carried out. Nevertheless, all these pregnancies should be considered ‘at risk’, especially for the mothers that can develop variceal bleeding, hepatic failure, jaundice, thrombocytopenia and linalve aneurysm rupture [55]. Foetal loss is also possible. The more dreadful complication is variceal bleeding (20–25%) [1]; especially during the second and third trimester when maternal blood volume is expanded and foetus and uterus dimension are increased, causing compression on inferior cava vein and collateral vessels [56]. For this reason, it is desirable to check each patient at early second trimester with an upper endoscopy and, in case of positive finding, to start prophylactic treatment with beta-blockers [1]. If oesophageal varices are known before pregnancy, they should be treated endoscopically by band ligation. In case of acute bleeding during pregnancy, the approach is also endoscopic [57].

Use of vasopressin is contraindicated in pregnancy [1]. Sclerotherapy seems effective and safe for both, mother and foetus. Variceal band ligation and butyl-cyanoacrylate injection have been executed and resulted safe. Propranolol, which is safe in pregnancy, may be a better option once acute bleeding has been controlled [57]. Caesarean section may reduce the risk of bleeding in patients with large oesophageal varices, but it is not recommended as a routine practice. If possible, a vaginal delivery is desirable [1].

As regard to other sequelae related to cirrhosis (ascites, spontaneous bacterial peritonitis, portosystemic encephalopathy), they rarely occur during pregnancy. Ascites is a very rare event; however, if necessary, depleting therapy is based on sodium restriction and diuretics, as for nonpregnant women with cirrhosis [28]. Hepatic encephalopathy can be caused by particular conditions like hypoxia, infections and gastrointestinal haemorrhages; in these cases, spinal and general anaesthesia during delivery should be avoided for the risk of hypotension and worsening of encephalopathy [28].

PREGNANCY AND LIVER TRANSPLANTATION

Pregnancy is a real opportunity for women recipients of orthotopic liver transplantation (OLT). Although a successful pregnancy is possible, it must be considered at risk. Maternal and foetal complications can occur, such as pre-eclampsia, hypertension, anaemia, renal dysfunction, diabetes, infections, prematurity, low weight at birth and miscarriage [2].

Obstetrical syndrome associated with OLT may depend by several factors such as defecteive deep placentation, uterine vascular bed and side effects of immunosuppressive therapy on uteroplacental arteries, as reported in National Transplantation Pregnancy Registry (NTPR), likewise immunosuppressive therapy can carry risk of miscarriage, prematurity, intrauterine growth retardation and low birth rate [58].

Studies have been performed to compare clinical courses of pregnancies in recipients of liver and renal transplantation, showing that outcomes of pregnancy after OLT are better than those after renal transplantation [59].

Vaginal delivery is possible but, because of high incidence of complications, the practice of Caesarean section is high, about 40%. Similarly, as there is a high incidence of premature delivery, in particular due to significant risk of premature membrane rupture (40%), pregnancy course must be closely monitored by a team of transplant hepatologists and experienced obstetrics [2]. Female liver transplant recipients who are planning a pregnancy should be adequately counselled about the optimal timing of become pregnant, mode of delivery and risks associated with immunosuppressive therapy. Furthermore, they should also be recommended on methods of contraception if pregnancy is not planned [59].

As clinical effect of immunosuppressive drugs reaches the peak 1 year after transplant reducing the risk of allograft rejection, it is advised to plan pregnancy about 18 months up to 2 years after transplantation to minimize foetal exposure to high doses of immunosuppressant drugs [2,59].

The use of immunosuppressive therapy after liver transplantation is unavoidable. All immunosuppressive agents cross the placenta and enter into foetal circulation with potentially dangerous effects in utero. The immunosuppressive agents 6
such as azathioprine, cyclosporine and mycophenolic acid have been shown to be teratogenic in animals. The risk of birth defects is almost similar for all agents; some drugs, like calcineurin inhibitors can lead to prematurity risk and others (like cyclosporine) could have their effect on renal function increasing the risk of pre-eclampsia [58]. Tacrolimus seems to give lower incidence of complications gaining a better control of hepatic function [60]. Obviously, hepatic function must be strictly checked along the whole pregnancy and every abnormalities should be managed in the same way as in nonpregnant women [2].

As regard to breastfeeding mothers with OLT can safely use prednisone or other glucocorticoids. The infant exposure of tacrolimus with milk is very low, and therefore, its administration may be compatible with breastfeeding. Data collected from the NTPR indicate no adverse outcomes in infants who were breastfed during maternal cyclosporine use; insufficient evidence is present in the literature about azathioprine’s teratogenicity [2]. Nevertheless, it is advised to avoid breast feed in the first few months post-transplantation where immunosuppressive therapy is at high serum level.

REFERENCES

29 Pan CQ, Duan ZP, Bhamidimarri KR et al. An Algorithm for risk
Dear Author,

During the copy-editing of your paper, the following queries arose. Please respond to these by marking up your proofs with the necessary changes/additions. Please write your answers on the query sheet if there is insufficient space on the page proofs. Please write clearly and follow the conventions shown on the attached corrections sheet. If returning the proof by fax do not write too close to the paper’s edge. Please remember that illegible mark-ups may delay publication.

Many thanks for your assistance.

<table>
<thead>
<tr>
<th>Query reference</th>
<th>Query</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AUTHOR: A running head short title was not supplied; please check if this one is suitable and, if not, please supply a short title of up to 40 characters that can be used instead.</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>AUTHOR: Please check the text of summary.</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>AUTHOR: The set of keywords is extracted from the supplied PDF source file. Please check if the keywords are okay.</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>AUTHOR: Please check the heading levels.</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>AUTHOR: Please check this website address and confirm that it is correct. (Please note that it is the responsibility of the author(s) to ensure that all URLs given in this article are correct and useable.)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>AUTHOR: Please check the edit made in the sentence “The Immunosuppressive... in animals”.</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>AUTHOR: Please provide the article title for reference [21].</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>AUTHOR: References [28] and [58] are identical. Hence, reference [58] is deleted and rest of the references is renumbered. Please check.</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>AUTHOR: Please provide the volume number for reference [58].</td>
<td></td>
</tr>
</tbody>
</table>